[go: up one dir, main page]

ES2059565T3 - Virus mva de la vacuna, recombinante. - Google Patents

Virus mva de la vacuna, recombinante.

Info

Publication number
ES2059565T3
ES2059565T3 ES89100038T ES89100038T ES2059565T3 ES 2059565 T3 ES2059565 T3 ES 2059565T3 ES 89100038 T ES89100038 T ES 89100038T ES 89100038 T ES89100038 T ES 89100038T ES 2059565 T3 ES2059565 T3 ES 2059565T3
Authority
ES
Spain
Prior art keywords
recombinant
mva
vaccine
vaccinia
patent affects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89100038T
Other languages
English (en)
Inventor
Werner Dr Altenburger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2059565T3 publication Critical patent/ES2059565T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE PATENTE AFECTA A VACCINIA - VIRUS RECOMBINANTES DERIVADOS DEL VIRUS ANKARA MODIFICADO (MVA) Y QUE CONTIENEN UNA SECUENCIA DE DNA QUE CODIFICA PARA UN ANTIGENO EXTRAÑO. POR LO DEMAS, LA PATENTE AFECTA A VACUNAS QUE CONTIENEN UN VIRUS SEMEJANTE EN UNA FORMA APROPIADA PARA INYECCION, ASI COMO EL PROCESO PARA SU OBTENCION. ADEMAS, LA PATENTE AFECTA A LA APLICACION DE UN VACCINIA - VIRUAS RECOMBINANTE MVA PARA LA OBTENCION DE UNA PROTEINA HETEROLOGA EN CELULAS EUCARIOTICAS.
ES89100038T 1988-01-12 1989-01-03 Virus mva de la vacuna, recombinante. Expired - Lifetime ES2059565T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH8588 1988-01-12

Publications (1)

Publication Number Publication Date
ES2059565T3 true ES2059565T3 (es) 1994-11-16

Family

ID=4178924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89100038T Expired - Lifetime ES2059565T3 (es) 1988-01-12 1989-01-03 Virus mva de la vacuna, recombinante.

Country Status (13)

Country Link
US (1) US5185146A (es)
EP (1) EP0324350B1 (es)
JP (1) JP2589797B2 (es)
AT (1) ATE97164T1 (es)
AU (1) AU619235B2 (es)
CA (1) CA1341245C (es)
DE (1) DE58906121D1 (es)
DK (1) DK11789A (es)
ES (1) ES2059565T3 (es)
IE (1) IE63619B1 (es)
NZ (1) NZ227562A (es)
PH (1) PH25747A (es)
ZA (1) ZA8997B (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
CA1340203C (en) * 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
AT400955B (de) * 1989-03-08 1996-05-28 Health Research Inc Rekombinantes pockenvirus-wirtsselektionssystem
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
WO1992016616A1 (en) * 1991-03-20 1992-10-01 Virogenetics Corporation Malaria recombinant poxvirus vaccine
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) * 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US6869793B2 (en) * 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6416779B1 (en) 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6572874B1 (en) 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US6582693B2 (en) * 1998-11-30 2003-06-24 Lemery, S.A. De C.V. Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
AU5397100A (en) * 1999-05-28 2000-12-18 Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
ES2306670T3 (es) 1999-10-22 2008-11-16 Sanofi Pasteur Limited Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
EP1418940A4 (en) 2000-03-02 2006-09-20 Univ Emory DNA EXPRESSION VECTORS AND METHODS OF USE
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US6682743B2 (en) * 2000-03-14 2004-01-27 Bavarian Nordic A/S Altered strain of the modified vaccinia virus ankara (MVA)
PT1282702E (pt) * 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
CN1176945C (zh) * 2001-02-01 2004-11-24 中国人民解放军第二军医大学 疟原虫融合抗原及其制法和用途
PT1372710E (pt) * 2001-03-08 2009-12-21 Us Gov Health & Human Serv Vam modificado que expressa os genes gag e pol do envelope de vih
UA82466C2 (uk) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
DE10144664B4 (de) * 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
EP2172552A3 (en) 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Recombinant nucleic acids comprising regions of AD6
WO2003047617A2 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
PL213326B1 (pl) * 2001-12-10 2013-02-28 Bavarian Nordic As Formulacja zawierajaca wirus ospy, sposób jej otrzymywania i zastosowanie
WO2003050268A2 (en) * 2001-12-12 2003-06-19 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
DK1434858T4 (en) * 2002-09-05 2019-04-01 Bavarian Nordic As PROCEDURE FOR AMPLIFICATION OF A POXVIRUS UNDER SERUM-FREE CONDITIONS
AU2003297499A1 (en) * 2002-12-23 2004-07-22 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
AU2004291024B2 (en) * 2003-02-20 2009-09-17 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Novel insertion sites in pox vectors
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
CA2610919C (en) 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
US20090060947A1 (en) * 2006-05-19 2009-03-05 Sanofi Pasteur, Inc. Immunological compositions
US20080010527A1 (en) * 2006-06-26 2008-01-10 Inventec Corporation Method of solving BIST failure of CPU by means of BIOS and maximizing system performance
US20100011451A1 (en) * 2006-09-08 2010-01-14 Paul Chaplin Phenotypic and genotypic differences of mva strains
US7807146B2 (en) 2006-10-06 2010-10-05 Bn Immunotherapeutics, Inc. Methods for treating cancer with a recombinant MVA expressing HER-2
JP2011511640A (ja) 2008-02-12 2011-04-14 サノフィ パストゥール リミテッド ポックス・ウイルスの精製方法
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
US20110159031A1 (en) * 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
CA2786333C (en) 2010-01-28 2018-03-20 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
MA34087B1 (fr) 2010-03-12 2013-03-05 Merial Ltd Vaccins recombinants contre le virus de la langue bleue et leurs utilisations
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
CN109266622B (zh) 2012-08-01 2023-05-09 巴法里安诺迪克有限公司 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗
EP3639851A1 (en) 2012-09-04 2020-04-22 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
EP3971298A3 (en) 2013-11-28 2022-04-27 Bavarian Nordic A/S Compositions and methods for inducing an enhanced immune response using poxvirus vectors
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
IL248511B (en) 2014-05-13 2022-07-01 Bavarian Nordic As Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
UA125013C2 (uk) 2014-09-03 2021-12-29 Баваріан Нордік А/С Вакцинна комбінація та спосіб індукування імунної відповіді проти філовірусу у суб'єкта
US10561722B2 (en) 2014-09-03 2020-02-18 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
PH12017500449B1 (en) 2014-09-26 2022-07-22 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
JP6887955B2 (ja) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 組換え体発現系のアッセイ
CR20230191A (es) 2015-05-20 2023-07-06 Dana Farber Cancer Inst Inc NEOANTIGENOS COMPARTIDOS (Div. exp 2017-584)
CN108368157B (zh) 2015-12-15 2022-04-15 扬森疫苗与预防公司 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
CA3018748A1 (en) 2016-03-31 2017-10-05 Neon Therapeutics, Inc. Neoantigens and methods of their use
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EA201892735A1 (ru) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
MA46230B1 (fr) 2016-09-15 2020-10-28 Janssen Vaccines & Prevention Bv Mutations de protéine d'enveloppe du vih stabilisant la forme trimère
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
SI3580561T1 (sl) 2017-02-12 2024-04-30 Biontech Us Inc. Metode, osnovane na hla, in njihove sestave ter uporabe
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
US11229693B2 (en) 2017-06-15 2022-01-25 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding HIV antigens, and methods of use thereof
JP7253529B2 (ja) 2017-07-19 2023-04-06 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
JP7236543B2 (ja) 2018-12-21 2023-03-09 ビオンテック ユーエス インコーポレイテッド Ｈｌａクラスｉｉ特異的エピトープの予測およびｃｄ４＋ ｔ細胞の特徴付けのための方法およびシステム
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
JP2023528805A (ja) 2020-05-26 2023-07-06 ディオニス セラピューティクス インコーポレイテッド 核酸人工ミニプロテオームライブラリー
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2021400424A1 (en) 2020-12-14 2023-07-06 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
EP4426829A1 (en) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
AU2023302376A1 (en) 2022-07-08 2025-01-16 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) * 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0111385A1 (en) * 1982-11-26 1984-06-20 Dow Corning Corporation Antimony oxide-containing organosilicon resins
WO1984002077A1 (en) * 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses

Also Published As

Publication number Publication date
DK11789A (da) 1989-07-13
EP0324350B1 (de) 1993-11-10
EP0324350A1 (de) 1989-07-19
JP2589797B2 (ja) 1997-03-12
CA1341245C (en) 2001-06-05
ZA8997B (en) 1989-09-27
AU2774389A (en) 1989-07-20
DK11789D0 (da) 1989-01-11
JPH025860A (ja) 1990-01-10
DE58906121D1 (de) 1993-12-16
US5185146A (en) 1993-02-09
ATE97164T1 (de) 1993-11-15
AU619235B2 (en) 1992-01-23
NZ227562A (en) 1992-04-28
PH25747A (en) 1991-10-18
IE63619B1 (en) 1995-05-17
IE890063L (en) 1989-07-12

Similar Documents

Publication Publication Date Title
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
EA200100425A1 (ru) Новые способы терапевтической вакцинации
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
DK0489968T3 (da) Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
ES2069742T3 (es) Proteina de la capsida del calicivirus felino y secuencia nucleotida.
ATE134195T1 (de) Peptidfragmente von hiv
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
ES8600938A1 (es) Un procedimiento para preparar el antigeno de superficie de la hepatitis b
ES2039239T3 (es) Vacuna contra el virus varicela-zoster.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
SE8105516L (sv) Syntetisk dna och forfarande for framstellning derav
ES2118242T3 (es) Vacunas anti virus de la inmunodeficiencia felina (fiv).
ATE176913T1 (de) Faser-hemagglutinin von b. pertussis
ES2074422T3 (es) Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso.
ES2085163T3 (es) Vacunas contra los parasitos metazoos.
DE68926274D1 (de) Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
WO1988000973A1 (fr) ADNs A PLASMIDES RECOMBINANTS, CODANT POUR LA SYNTHESE DE SUBSTANCES POLYPEPTIDES POUR UN VACCIN CONTRE L'HEPATITE A
AR124382A1 (es) Parapoxvirus modificado que tiene inmunogenicidad aumentada

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 324350

Country of ref document: ES